QUEBEC

Rio2 Announces Receipt of RCA Resolution for the Fenix Gold Project & C$10 Million Private Placement

Retrieved on: 
Lundi, avril 8, 2024
Technical report, Feasibility, TSX Venture Exchange, Growth, Atacama Region, Offering, Rule, Part, Gold, Regulation, Sale, Feasibility study, News, National instrument, QP, Share (finance), Endeavour, File, Agent, MAIG, Oil, RCA, BVL, Mining

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Rio2 Limited (“Rio2” or the “Company”) (TSXV: RIO; OTCQX: RIOFF; BVL: RIO) today announces that its Chilean subsidiary, Fenix Gold Limitada (“Fenix Gold”), has received the formal Resolución de Calificación Ambiental (Environmental Qualification Resolution, or RCA) for its Fenix Gold Project (the “Project”) located in the Maricunga Mineral Belt of the Atacama Region, Chile.

Key Points: 
  • The RCA has been issued following the approval of the Project’s Environmental Impact Assessment previously announced on December 20, 2023.
  • The receipt of the RCA now allows Fenix Gold to advance permitting activities for the Project.
  • The current timing for receipt of these principal permits is by the end of July 2024.
  • The Company is seeking to finance a substantial component of the initial capital costs by way of Project related debt.

Brunswick Signs Right to Repurchases 0.5% NSR on Select Claims at Mirage

Retrieved on: 
Lundi, avril 8, 2024
Mirage, BRW, OTCQB, TSX, Lithium, NSR, Teahouse

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to announce that it signed an agreement with Sirios Resources (“Sirios”) to repurchase an existing 0.5% NSR on certain claims within the Mirage Project, located in the Eeyou Istchee James Bay region of Quebec.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to announce that it signed an agreement with Sirios Resources (“Sirios”) to repurchase an existing 0.5% NSR on certain claims within the Mirage Project, located in the Eeyou Istchee James Bay region of Quebec.
  • Mr. Killian Charles, President and CEO of BRW, commented: “We are excitedly looking forward to the approaching release of the first wave of results from our Winter 2024 campaign at Mirage as these results will continue to demonstrate the growing exploration prospectivity at Mirage.
  • The payment schedule is subject to the following constraints:
    Share amount is calculated on the 10-day Volume Weighted Average Share Price preceding the date of the payment and is subject to a $0.40 minimum share price.
  • Upon start of mineral extraction over the claims covered by this agreement, Brunswick will make a further milestone payment to Sirios of $250,000 in cash or an amount in shares (share amount is calculated on the 10-day Volume Weighted Average Share Price preceding the date of the payment and is subject to a $0.40 minimum share price) or a combination of both, at Brunswick’s discretion.

i-80 Announces C$86 Million Bought Deal Public Offering of Units

Retrieved on: 
Lundi, avril 8, 2024
Indian stock exchange, Offering, News, Toronto Stock Exchange, Prospectus, TSX, Unit, Security (finance)

RENO, Nev., April 08, 2024 (GLOBE NEWSWIRE) -- i-80 Gold Corp. (TSX:IAU) (NYSE:IAUX) (“i-80” or the “Company”) is pleased to announce that it has entered into an agreement with National Bank Financial Inc., as lead underwriter, on behalf of a syndicate of underwriters (collectively, the “Underwriters”) under which the Underwriters have agreed to purchase, on a bought deal basis, 51,882,000 units of the Company (“Units”) at a price of C$1.65 per Unit for gross proceeds of C$85,605,300 (the “Offering”). Each Unit is comprised of one common share (each a “Common Share”) and one-half of one Common Share purchase warrant (each whole warrant a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$2.15 for a period of 48 months following the closing of the Offering.

Key Points: 
  • Each Unit is comprised of one common share (each a “Common Share”) and one-half of one Common Share purchase warrant (each whole warrant a “Warrant”).
  • Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$2.15 for a period of 48 months following the closing of the Offering.
  • The net proceeds of the Offering, inclusive of the over-allotment option if exercised, will be used to advance the development of the Company’s mineral properties and for general corporate purposes, as more particularly described in the short form prospectus.
  • This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States.

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Retrieved on: 
Lundi, avril 8, 2024
FACC, American College, Atrial flutter, Patient, Journal, History, Doctor of Philosophy, MD, Ventricular fibrillation, ACC, Pharmaceutical industry

“The promising results of this real-world design study demonstrated patients’ ability to self-manage multiple episodes of PSVT with etripamil,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals.

Key Points: 
  • “The promising results of this real-world design study demonstrated patients’ ability to self-manage multiple episodes of PSVT with etripamil,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals.
  • CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, if approved, will be the first rapid, reliable, and at-the-ready option in the acute treatment of PSVT.
  • NODE-303 (ClinicalTrials.gov ID NCT04072835 ) evaluated self-administered etripamil (70 mg, nasal spray) in an outpatient setting for up to multiple episodes of PSVT, without prior test dosing.
  • Both the presentation and publication will be available on the Milestone Pharmaceuticals corporate website at the conclusion of the ACC presentation.

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

Retrieved on: 
Lundi, avril 8, 2024
Karolinska University Hospital, EudraCT, PD, L-DOPA, Patient, IGX, Doctor of Philosophy, MD, TSX, Clinical trial, Pharmaceutical industry

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial.

Key Points: 
  • SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial.
  • MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD.
  • The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period.
  • Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents.

Wesdome Provides Kiena Exploration Update; Drilling Continues to Grow Kiena Deep and Intercept High Grades Near Mine Infrastructure

Retrieved on: 
Lundi, avril 8, 2024
Gold, 3D, TSX, OTCQX, WDO, Fault (geology), Growth

As the main ramp at Kiena Deep progresses towards the 136-level by year end, additional drill platforms are being established to facilitate drilling in previously discovered but not fully explored zones.

Key Points: 
  • As the main ramp at Kiena Deep progresses towards the 136-level by year end, additional drill platforms are being established to facilitate drilling in previously discovered but not fully explored zones.
  • Drilling is also expected to continue to build upon our early success and aim to expand and extend the known size of these zones.
  • Over the past several years, underground drilling has primarily focussed on testing areas proximal to the Kiena Deep A Zone.
  • The Kiena Deep A Zone now extends continuously from 1,100 meters below surface and beyond current resources which extend to approximately 1,800 meters.

Savaria Announces the Acquisition of the Dumbwaiter and Material Lift Assets of D.A. Matot, Inc.

Retrieved on: 
Lundi, avril 8, 2024
TSX, Movement, Acquisition, Growth, Bank

LAVAL, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- Savaria Corporation (“Savaria”) (TSX: SIS) a global leader in the accessibility industry, today announced it has acquired all the dumbwaiter and material lift assets of D.A.

Key Points: 
  • LAVAL, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- Savaria Corporation (“Savaria”) (TSX: SIS) a global leader in the accessibility industry, today announced it has acquired all the dumbwaiter and material lift assets of D.A.
  • Matot’s customer base includes current Savaria dealers as well as large passenger elevator companies.
  • In 2023, Matot’s dumbwaiter and material lift business generated US $6.3 million (C $8.6 million) in revenue with US $1.1 million (C $1.5 million) in EBITDA.
  • The Kelair dampers business is not part of this transaction and remains with the Matot family.

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

Retrieved on: 
Vendredi, avril 5, 2024
Symantec Endpoint Protection, CRL, IGX, Chronic pain, Buprenorphine, TSX, FDA, Food, Pharmaceutical industry

SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted abbreviated new drug application (“ANDA”) for Buprenorphine Buccal Film.

Key Points: 
  • SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted abbreviated new drug application (“ANDA”) for Buprenorphine Buccal Film.
  • The CRL includes a request for additional Pharmaceutical Quality information.
  • Buprenorphine Buccal Film, which incorporates IntelGenx’s VersaFilm® technology in a novel formulation, is a generic version of Belbuca®, an opioid that is used to manage chronic pain severe enough to require daily, around-the-clock, long-term treatment with an opioid, when other pain treatments are inadequate.
  • Approved by the FDA in 2015, Belbuca® is applied to the oral or buccal mucosa every 12 hours and comes in seven strengths ranging from 0.075 mg to 0.9 mg.

New victory against mining giant Glencore’s anti-union practices

Retrieved on: 
Jeudi, avril 4, 2024
FTQ, Tribunal, Glencore, Superior court, Steel, USW, TAT, Light, Raglan Mine

Glencore had eliminated the security service positions after United Steelworkers union members refused the company's proposed collective agreement.

Key Points: 
  • Glencore had eliminated the security service positions after United Steelworkers union members refused the company's proposed collective agreement.
  • We will support our members to the end against anti-union practices," said United Steelworkers Quebec Director Dominic Lemieux.
  • Nicholas Marchand, president of the security officers' local, is delighted with this victory in the long legal saga.
  • "It's awful what Glencore has put us through since 2021, we're happy with this new legal victory.

Puma Exploration Intercepts Widespread Alteration with VG at Tiger Gold Zone and Expands Ongoing Drilling Program

Retrieved on: 
Jeudi, avril 4, 2024
Galena, PUMA, Tiger, Gold, Nature, TGZ, OTCQB, Mining

The Tiger Gold Zone is a new gold area discovered last year by applying the Company’s successful discovery model.

Key Points: 
  • The Tiger Gold Zone is a new gold area discovered last year by applying the Company’s successful discovery model.
  • The core exhibits the same pervasive alteration and mineralization characteristic of the Lynx Gold Zone.
  • Last year, Puma discovered a new prospective area, the Cheetah Gold Zone ("CHGZ"), which returned 6.69 g/t Au in the Company’s initial trenching and sampling exploration program.
  • This preliminary scout drilling and continued systematic surface exploration work will enable us to prove the extent of the gold mineralized zone.